Objective: To study the effect and safety of Fenofibrate in uncomplicated hyperbilirubinemia in newborn with 6-month follow-up. Materials and Methods: This is a randomized controlled clinical trial conducted in 60 normal term neonates admitted for uncomplicated hyperbilirubinemia in NICU at Sir T G Hospital, Bhavnagar from January 2012 to December 2012. The data included: age, sex, total serum bilirubin (TSB), weight and duration of phototherapy. All neonates enrolled in the study received phototherapy. They were divided in two groups of 30 each: control group A and group B receiving Fenofibrate (100 mg/kg single dose). There was statistically insignificant difference between the parameters of age, sex, weight and TSB between the two groups at hospitalization. Data was analyzed by using appropriate statistical methods. Results: Mean values for total serum bilirubin in Fenofibrate group B at 24 and 48 hours after admission were significantly lower than those for control group A (p<0.0001,  p=0.0001). There was no significant difference in fall of TSB between 24 and 48 hours. The mean duration of phototherapy in Fenofibrate group (44.8h: 24-72h) was significantly shorter than that in control group (55.2 h: 24‐96 h) (P=0.02). There were no side effects of the drug observed during the study and during 6 months follow up period. Conclusion: Fenofibrate as a single 100 mg/kg dose in healthy full term neonates, is effective and a safe drug (till six-month follow-up) for neonatal hyperbilirubinemia, that can decrease the time needed for phototherapy and hence hospitalization. Effect of a single dose seems to wane after 24 hours.

slowing dramatically from 2006 to 2008. JoinPoint regression analysis of different age groups demonstrates that the slower rate of decline from 2006 may be due to stubbornly high numbers of deaths in the 35e44 age group. Lastly the National figures on mortality from CHD are shown to be misleading as many people are still dying from CHD just when they have crossed the 75-year old exclusion criteria; as a result a delay in mortality is presented as prevention of mortality from CHD. Discussion There is a danger that previous successes are being offset by high rates in the younger cohorts, and that the overall trend may be eventually be reversed. There is still work to be done in reducing risk factors and also applying treatments that have had a proven positive impact (such as revascularisation) more effectively. Statistically significant changes in declining CHD mortality rates. Future work This 10 000 word report formed the basis of a funding application to the British Heart Foundation for a follow-up to the United Kingdom Heart Attack Study. Background Previous studies have demonstrated a relationship between pre-existing anaemia and inpatient mortality after percutaneous coronary intervention (PCI). There is limited data looking at the impact of baseline Haemoglobin and long term outcome after primary PCI. Methods Clinical information was analysed from a prospective database on 2357 STEMI patients who underwent Primary PCI between January 2004 and May 2010 at a London centre. Information was entered at the time of procedure and outcome assessed by all-cause mortality information provided by the Office of National Statistics via the BCIS/CCAD national audit. Anaemia was defined according to WHO definition of Hb greater than or equal to 12 g/dl for females and 13 g/dl for males. Results 471 (20%) patients were anaemic at presentation. The anaemic cohort, were older (72.2 vs 62.4, p<0.0001), had higher incidence of diabetes (27% vs 15%, p<0.0001), hypertension (42 vs 35%, p¼0.01), hypercholesterolaemia (40 vs 30%, p¼0.007), previous PCI (13 vs 7%, p¼0.01), and previous MI (23% vs 12%, p<0.0001). There were similar incidences of three-vessel disease and cardiogenic shock. Over a 3-year follow-up period there was significantly higher all cause mortality in the anaemic group compared to the normal Hb group (20.4% vs 13.5%, p<0.0001). See Abstract 18

at PPCI in elderly patients such as SENIOR PAMI (Grines, 2005) and TRIANA (Bueno, 2009) the minimum age for inclusion was 70 yrs and 75 yrs respectively. With an ageing population in the western world, about 20% of patients admitted for suspected STEMI are $80 yrs. We evaluated the outcome of PPCI in patients $80 yrs who were admitted to our unit with STEMI. Methods Our PPCI service was started in September 2009 and we analysed all the patients who were $80 yrs presenting to the PPCI service between September 2009 and September 2010 (13 months). Prospectively entered data were obtained from our dedicated cardiac service database system (Philips CVIS). Mortality data were obtained from the summary care record (SCR) database. Follow-up data were obtained from patients' respective district general hospitals and general practitioners medical records. Results Of the 998 patients who were admitted to our unit for primary PCI for suspected STEMI during the study period, 183 (18.3%) were $80 yrs of age. After excluding 51 patients (27.9%) who did not undergo PPCI, we included 132 (70.1%) patients for analysis. Of those who were included in the study (n¼132, 63 female), the mean age was 8563.95 yrs (range 80e99 yrs, median 85 yrs). There were 20 diabetics (15.2%) and 39 (29.5%) had previous myocardial infarction. Ten patients (7.6%) were in cardiogenic shock on arrival of which 9 (90%) had an Intra aortic balloon pump (IABP). The infarct related vessel was the right coronary in 42.4% and left anterior descending in 37.1%. Drug eluting stents were used in 40.2% of patients. In-hospital and 30-day mortality was 14.4% and 19.7% respectively. There was a significant difference in the mortality between patients age <80 yrs and those $80 yrs (Abstract 45 figure 1). In patients $80 yrs, mortality and bleeding risk increased markedly with advancing age (Abstract 45 table 1).Abstract 45 Figure 1 Abstract 45 Table 1 % 80e84 yrs (N[62)